Wall Street Zen Downgrades Pacira BioSciences (NASDAQ:PCRX) to Buy

Pacira BioSciences (NASDAQ:PCRX) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Other research analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Truist Financial decreased their price objective on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Barclays assumed coverage on Pacira BioSciences in a report on Tuesday, December 9th. They set an “equal weight” rating and a $27.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Pacira BioSciences in a report on Friday, January 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $30.75.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $21.91 on Friday. The stock’s 50-day simple moving average is $22.65 and its 200-day simple moving average is $23.85. The firm has a market capitalization of $942.57 million, a PE ratio of 146.07 and a beta of 0.24. Pacira BioSciences has a fifty-two week low of $18.80 and a fifty-two week high of $27.64. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.78 and a current ratio of 5.26.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing the consensus estimate of $0.85 by ($0.28). Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.16%. The company had revenue of $196.87 million during the quarter, compared to analysts’ expectations of $201.93 million. During the same quarter in the prior year, the company earned $0.91 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. As a group, equities research analysts forecast that Pacira BioSciences will post 2.41 EPS for the current fiscal year.

Insider Transactions at Pacira BioSciences

In related news, SVP Lauren Riker sold 4,000 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $20.81, for a total transaction of $83,240.00. Following the transaction, the senior vice president owned 52,313 shares of the company’s stock, valued at $1,088,633.53. This trade represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Shawn Cross sold 15,896 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $25.03, for a total value of $397,876.88. Following the sale, the chief financial officer directly owned 56,250 shares of the company’s stock, valued at approximately $1,407,937.50. This represents a 22.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 30,416 shares of company stock worth $744,315. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

Several hedge funds have recently modified their holdings of the stock. Doma Perpetual Capital Management LLC grew its position in Pacira BioSciences by 49.7% in the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company’s stock valued at $69,613,000 after buying an additional 897,255 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Pacira BioSciences by 0.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,163,473 shares of the company’s stock worth $55,751,000 after acquiring an additional 11,831 shares during the period. Balyasny Asset Management L.P. lifted its stake in shares of Pacira BioSciences by 36.1% in the 2nd quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock worth $50,925,000 after acquiring an additional 565,288 shares during the period. American Century Companies Inc. boosted its holdings in shares of Pacira BioSciences by 16.6% in the third quarter. American Century Companies Inc. now owns 1,378,513 shares of the company’s stock valued at $35,524,000 after acquiring an additional 196,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Pacira BioSciences by 0.5% during the second quarter. Geode Capital Management LLC now owns 1,143,190 shares of the company’s stock worth $27,326,000 after acquiring an additional 5,658 shares during the period. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences News Summary

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Record EXPAREL sales — Pacira said EXPAREL delivered its strongest fourth-quarter performance in three years, driven by 7% volume growth, signaling solid demand for its core product. GlobeNewswire Release
• Neutral Sentiment: Company provided FY-2026 revenue guidance of $745.0 million to $770.0 million (versus consensus ~$766.9M); range implies growth but sits slightly below the consensus midpoint, leaving interpretation mixed for investors. Guidance Detail
• Neutral Sentiment: Full earnings materials and call resources are available (earnings press release, slide deck and call transcripts), useful for investors wanting management commentary on margin drivers and expense cadence. Slide Deck Earnings Call Transcript
• Negative Sentiment: Earnings and revenue missed estimates — Pacira reported Q4 EPS of $0.57 vs. consensus $0.85 and revenue of $196.9M vs. $201.9M expected; the EPS shortfall and top-line miss are primary drivers of the negative price reaction. MarketBeat Earnings Summary
• Negative Sentiment: Rising expenses pressured margins — management flagged higher operating costs that reduced net income and contributed to the EPS miss, raising near-term profitability concerns. Zacks Coverage

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.